Navigation Links
CTI Appoints Monique Greer, Senior Vice President, Corporate Communications and Investor Relations

SEATTLE, Nov. 12, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, announced today the appointment of Monique Greer as Senior Vice President, Corporate Communications and Investor Relations.  Ms. Greer will be responsible for leading CTI's external and internal communications strategies and will report directly to James A. Bianco, M.D., President and Chief Executive Officer.

"Monique is a key hire to drive consistent communications globally, as we transition from a product development organization to a commercial organization," said James Bianco.  "She has an excellent reputation in the biotechnology industry for developing and executing strategic, results-driven communications programs that advance business objectives.  We believe Monique's recent hematology/oncology commercial experience, management discipline and entrepreneurial drive will serve CTI well as we execute on our global strategy to deliver results for both patients and shareholders."

Ms. Greer has more than 17 years' experience planning and implementing strategic biotech/healthcare corporate communications, investor and media relations, and advocacy relations programs in support of product development, commercialization and strategic initiatives.  Most recently, Ms. Greer was Vice President of Corporate Communications and Investor Relations for Allos Therapeutics, Inc. (recently acquired by Spectrum Pharmaceuticals).  Ms. Greer served previously as Senior Associate in the Corporate Communications and Investor Relations practice for WCG, a global communications agency, where she created and implemented integrated, strategic communications programs for the firm's clients in the United States and Europe.  She has also served as Senior Director, Corporate Communications and Investor Relations for Dendreon Corporation, as well as Director, Corporate Communications for Heska Corporation.  Ms. Greer received a bachelor of science in Business Administration from Northeastern University.

About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

Ed Bell
T: 206.282.7100
F: 206.272.4434

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
2. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
3. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
4. ViaCyte Appoints Steve Altman to its Board of Directors
5. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
6. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
7. BioNeutral Group Appoints Mr. Mark Lowenthal as Chief Executive and President
8. BioNeutral Group Appoints A New Member to the Board of Directors
9. Western Carolina University, College of Business Appoints New Director of Entrepreneurship and Innovation
10. JG Finneran Associates Appoints Chebios as its Exclusive Distributor in Italy
11. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
Breaking Biology Technology:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):